NCT07363811Recruiting
Large Granular Lymphocytes in mNSCLC Treated With Nivolumab
Large Granular Lymphocytes as a Prognostic Factor in Metastatic Non-small Cell Lung Cancer Treated With Nivolumab
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
Large granular lymphocytes (LGLs), which constitute 10-15% of peripheral blood mononuclear cells, are large lymphocytes with a round nucleus, large cytoplasm, and azurophilic granules in the cytoplasm. Most normal LGLs in peripheral blood are natural killer (NK) cells, but some are T lymphocytes. These cells cannot be measured by a standard complete blood count (CBC) test. These cells, which can be detected by peripheral smear, are expressed numerically and as a percentage relative to other cells. The aim of this study is to determine the relationship between the percentage of LGLs at baseline and at three months and the response and clinical parameters in participants with metastatic non-small cell lung cancer treated with nivolumab in second-line therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 15 Jan 2026
- Start date
- 1 Jul 2025
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Necmettin Erbakan University
- Diseases
- Lung cancer
- NCT number
- NCT07363811
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Jul 2025 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients diagnosed with mNSCLC who received nivolumab as adjuvant or perioperative therapy
- Those who have undergone palliative or curative radiotherapy within the last three months
- Patients who have used steroids in the last three months
Other illness
- Those with a second primary malignancy undergoing active treatment
- Those with additional hematological malignancies such as leukemia, lymphoma, or myelodysplastic syndrome
- Those with active viral/bacterial infections before nivolumab treatment
Other
- Those who have not signed the informed consent form
Who the study is looking for
- Histological and staging diagnosis of metastatic non-small cell lung cancer
- ECOG performance score between 0 and 2
- No contraindications for nivolumab
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology Coordinator of this site? Confirm its status | Konya | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.